Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 9, 2014, Pages 1565-1572

  Betts, J W ^a   Phee, L M ^a,b   Woodford, N ^a,c   Wareham, D W ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIN; COTRIMOXAZOLE; RIFAMPICIN; TIGECYCLINE; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; DRUG POTENTIATION; DRUG SENSITIVITY; GALLERIA MELLONELLA; IN VITRO STUDY; IN VIVO STUDY; INVERTEBRATE MODEL; LARVA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANT STENOTROPHOMONAS MALTOPHILIA INFECTION; NONHUMAN; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; GRAM-NEGATIVE BACTERIAL INFECTIONS; LEPIDOPTERA; MICROBIAL VIABILITY; MULTIDRUG RESISTANCE; PROCEDURES; SURVIVAL;

ANIMALS; COLISTIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; LEPIDOPTERA; MICROBIAL VIABILITY; MINOCYCLINE; RIFAMPIN; STENOTROPHOMONAS MALTOPHILIA; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84905989712     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2101-3     Document Type: Article

References (30)

1. Denton M, Kerr KG (1998) Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 11(1):57-80 (Pubitemid 28046016)
2. Krueger TS, Clark EA, Nix DE (2001) In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 41:71-78 (Pubitemid 33001462)
3. Poulos CD,Matsumura SO,Willey BM, Low DE, McGeer A (1995) In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob Agents Chemother 39(10):2220-2223
4. Avison MB, Higgins CS, Ford PJ, von Heldreich CJ, Walsh TR, Bennett PM(2002) Differential regulation of L1 and L2 β-lactamase expression in Stenotrophomonas maltophilia . J Antimicrob Chemother 49:387-389 (Pubitemid 34162634)
5. Zhang L, Li XZ, Poole K (2000) Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 44:287-293 (Pubitemid 30060721)
6. Giamarellos-Bourboulis EJ, Karnesis L, Galani I, Giamarellou H (2002) In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother 46:3997-3999 (Pubitemid 35403283)
7. Zelenitsky SA, Iacovides H, Ariano RE, Harding GKM (2005) Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 51:39-43 (Pubitemid 40040566)
8. Berg G, Roskot N, Smalla K (1999) Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomonas maltophilia. Antimicrob Agents Chemother 37:3594-3600 (Pubitemid 29491099)
9. Al-Jasser AM (2006) Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem. Ann Clin Microbiol Antimicrob 5:23
10. Toleman MA, Bennett PM, Bennett DMC, Jones RN, Walsh TR (2007) Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 13(4):559-565 (Pubitemid 46525100)
11. Noskin GA (2005) Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 41:S303-S314
12. Gordon NC, Wareham DW (2009) A Review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother 63:775-780
13. Drapeau CMJ, Grilli E, Petrosillo N (2010) Rifampicin combined regimens for Gram-negative infections: data from the literature. Int J Antimicrob Agents 35:39-44
14. Milne KEN, Gould IM (2012) Combination antimicrobial susceptibility testing of multidrug-resistant Stenotrophomonas maltophilia from cystic fibrosis patients. Antimicrob Agents Chemother 56(8):4071-4077
15. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25:11-25 (Pubitemid 40023341)
16. Wareham DW, Gordon NC, Hornsey M (2011) In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 66(5):1047-1051
17. Church D, Lloyd T, Peirano G, Pitout J (2013) Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis 45(4):256-270
18. Giamarellos-Bourboulis EJ, Karnesis L, Giamarellou H (2002) Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44:259-263 (Pubitemid 35454100)
19. Gülmez D, Cakar A, Sener B, Karakaya J, Hasçelik G (2010) Comparison of different antimicrobial susceptibility testing methods for Stenotrophomonas maltophilia and results of synergy testing. J Infect Chemother 16:322-328
20. Tascini C, Ferranti S, Messina F, Menichetti F (2000) In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect Dis 6:690-691 (Pubitemid 34966100)
21. Milne KEN, Gould IM (2010) Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index. J Antimicrob Chemother 65:82-90
22. Bergen PJ, Forrest A, Bulitta JB, Tsuji BT, Sidjabat HE, Paterson DL, Li J, Nation RL (2011) Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 55(11):5134-5142
23. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ (2005) The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 41(Suppl 5):S333-S340 (Pubitemid 41170380)
24. Verbist L, Gyselen A (1968) Antituberculous activity of rifampin in vitro and in vivo and the concentrations attained in human blood. Am Rev Respir Dis 98:923-932
25. Nicoletti M, Iacobino A, Prosseda G, Fiscarelli E, Zarrilli R, De Carolis E, Petrucca A, Nencioni L, Colonna B, Casalino M (2011) Stenotrophomonas maltophilia strains from cystic fibrosis patients: genomic variability andmolecular characterization of some virulence determinants. Int J Med Microbiol 301(1):34-43
26. Hornsey M, Wareham DW (2011) In vivo efficacy of glycopeptide-colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 55(7):3534-3537
27. Nicodemo AC, Araujo MRE, Ruiz AS, Gales AC (2004) In vitro susceptibility of Stenotrophomonas maltophilia isolates: comparison of disc diffusion, Etest and agar dilution methods. J Antimicrob Chemother 53:604-608 (Pubitemid 38499774)
28. Biswas S, Dubus JC, Reynaud-Gaubert M, Stremler N, Rolain JM (2013) Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France. Eur J Clin Microbiol Infect Dis 32(11):1461-1464
29. Hindler JA, Humphries RM (2013) Colistin MIC variability by method for contemporary clinical isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol 51(6):1678-1684
30. Vaara M (1992) Agents that increase the permeability of the outer membrane. Microbiol Rev 56:395-411